Additional ligand-neutralizing antibodies targeting TGFα or HB-EGF have demonstrated anti-proliferative activity in vitro and inhibition of tumor growth and high dose-tolerability in vivo [27,28,29]. This evidence concerns the gene TGFA and neoplasm.